Cambridge Investment Research Advisors
AVDL

Cambridge Investment Research Advisors’s Avadel Pharmaceuticals AVDL Stock Holding History

Cambridge Investment Research Advisors’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-72,216
Closed -$565K – 3624
2025
Q1 		$565K Sell
72,216
-3,465
-5% -$29K ﹤0.01% 2312
2024
Q4 		$795K Buy
+75,681
New +$919K ﹤0.01% 2046
2024
Q1 		– Sell
-11,921
Closed -$168K – 3311
2023
Q4 		$168K Buy
+11,921
New +$140K ﹤0.01% 2945

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cambridge Investment Research Advisors's AVDL Position: Q2 2025 in Review

Cambridge Investment Research Advisors sold out of Avadel Pharmaceuticals (AVDL) in Q2 2025, closing a stake of 72,216 shares — an estimated $565K sold.

Cambridge Investment Research Advisors first reported a position in AVDL in Q4 2023 and held it in 3 quarters. The position peaked at $795K in Q4 2024. 173 funds tracked by Wall St. Rank hold AVDL as of Q2 2025.

  • Cambridge Investment Research Advisors reported no remaining Avadel Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 72,216 Avadel Pharmaceuticals shares in Q2 2025, an estimated $565K.
  • Cambridge Investment Research Advisors first reported a position in Avadel Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • Cambridge Investment Research Advisors's Avadel Pharmaceuticals position peaked at $795K in Q4 2024.
  • 173 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2025.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2025, filed 31 Jul 2025.